Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer

Cancer Letters

Volumn 291, Issue 1, 2010, Pages 90-98

  Kong, Rui ^a   Sun, Bei ^a   Jiang, Hongchi ^a   Pan, Shangha ^a   Chen, Hua ^a   Wang, Shuangjia ^a   Krissansen, Geoffrey W ^b   Sun, Xueying ^a,b  

^a First Affiliated Hospital   (China)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Gemcitabine; Nuclear factor B; Pancreatic cancer; Small interference RNA

Indexed keywords

CASPASE 3; CYCLIN D2; GEMCITABINE; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA;

MUS MUSCULUS;

EID: 77949874727     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.001     Document Type: Article

References (48)

1. Beger H.G., Rau B., Gansauge F., Poch B., and Link K.H. Treatment of pancreatic cancer: challenge of the facts. World J. Surg. 27 (2003) 1075-1084
2. Kullmann F., Hollerbach S., Dollinger M.M., Harder J., Fuchs M., Messmann H., Trojan J., Gäbele E., Hinke A., Hollerbach C., and Endlicher E. Cetuximab plus Gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer 100 (2009) 1032
3. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., Saletti P., Bauer J., Figer A., Pestalozzi B., Köhne C.H., Mingrone W., Stemmer S.M., Tàmas K., Kornek G.V., Koeberle D., Cina S., Bernhard J., Dietrich D., and Scheithauer W. Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group, Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25 (2007) 2212-2217
4. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., and Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69 (2009) 2400-2407
5. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 5 (2002) 19-33
6. Neumann M., and Naumann M. Beyond IkappaBs: alternative regulation of NF-κB activity. FASEB J. 21 (2007) 2642-2654
7. Pan X., Arumugam T., Yamamoto T., Levin P.A., Ramachandran V., Ji B., Lopez-Berestein G., Vivas-Mejia P.E., Sood A.K., McConkey D.J., and Logsdon C.D. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin. Cancer. Res. 14 (2008) 8143-8151
8. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., and Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (2003) 90-97
9. Xiong H.Q., Abbruzzese J.L., Lin E., Wang L., Zheng L., and Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int. J. Cancer 108 (2004) 181-188
10. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., and Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer. Res. 5 (1999) 119-127
11. Liptay S., Weber C.K., Ludwig L., Wagner M., Adler G., and Schmid R.M. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int. J. Cancer 105 (2003) 735-746
12. Chandler N.M., Canete J.J., and Callery M.P. Increased expression of NF-κB subunits in human pancreaticcancer cells. J. Surg. Res. 118 (2004) 9-14
13. Greten F.R., Weber C.K., Greten T.F., Schneider G., Wagner M., Adler G., and Schmid R.M. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123 (2002) 2052-2063
14. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107 (2001) 135-142
15. Yebra M., Filardo E.J., Bayna E.M., Kawahara E., Becker J.C., and Cheresh D.A. Induction of carcinoma cell migration on vitronectin by NF-kappaB-dependent gene expression. Mol. Biol. Cell 6 (1995) 841-850
16. Arlt A., Gehrz A., Müerköster S., Vorndamm J., Kruse M.L., Fölsch U.R., and Schäfer H. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22 (2003) 3243-3251
17. Sebens S., Arlt A., and Schäfer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 177 (2008) 151-164
18. Melisi D., and Chiao P.J. NF-κB as a target for cancer therapy. Expert. Opin. Ther. Targets 11 (2007) 133-144
19. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., Philip P.A., Abbruzzese J., and Sarkar F.H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 65 (2005) 9064-9072
20. Müerköster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Fölsch U.R., and Schäfer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer 104 (2003) 469-476
21. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., and Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67 (2007) 3853-3861
22. Mamaghani S., Patel S., and Hedley D.W. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappa B activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC. Cancer. 9 (2009) 132
23. Bass B.L. Double-stranded RNA as a template for gene silencing. Cell 101 (2000) 235-238
24. Guo J., Verma U.N., Gaynor R.B., Frenkel E.P., and Becerra C.R. Enhanced chemosensitivity to irinotecan by RNA interference mediated down-regulation of the nuclear factor-κB p65 subunit. Clin. Cancer Res. 10 (2004) 3333-3341
25. Andrews N.C., and Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19 (1991) 2499
26. Chen H., Sun B., Pan S., Jiang H., and Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 20 (2009) 131-140
27. Ma L., Luo L., Qiao H., Dong X., Pan S., Jiang H., Krissansen G.W., and Sun X. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J. Hepatol. 46 (2007) 98-106
28. Mai Z., Blackburn G.L., and Zhou J.R. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis 28 (2007) 1217-1223
29. Wang D., Wang Z., Tian B., Li X., Li S., and Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int. J. Urol. 15 (2008) 435-441
30. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
31. Baud V., and Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug. Discov. 8 (2009) 33-40
32. Veiby O.P., and Read M.A. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin. Cancer Res. 10 (2004) 3262-3264
33. Takahashi-Yanaga F., and Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell. Signal. 20 (2008) 581-589
34. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., and Beger H.G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57 (1997) 1634-1637
35. Kornmann M., Ishiwata T., Itakura J., Tangvoranuntakul P., Beger H.G., and Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 55 (1998) 363-369
36. Yoshizawa J., Takizawa A., Takeuchi O., Hiraku O., Sasaki K., Morimoto Y., Atsuda K., Inoue G., Suzuki Y., Asanuma F., and Yamada Y. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother. Pharmacol. 64 (2009) 1211-1219
37. Makiyama A., Qin B., Uchino K., Shibata Y., Arita S., Isobe T., Hirano G., Kusaba H., Baba E., Akashi K., and Nakano S. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anticancer Drugs 20 (2009) 123-130
38. Walensky L.D. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ. 13 (2006) 1339-1350
39. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I., Jones D.P., and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
40. Casneuf V.F., Demetter P., Boterberg T., Delrue L., Peeters M., and Damme N.Van. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol. Rep. 22 (2009) 105-113
41. Liu F., Tan G., Li J., Dong X., Krissansen G.W., and Sun X. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci. 98 (2007) 1381-1387
42. Liu F., Wang P., Jiang X., Tan G., Qiao H., Jiang H., Krissansen G.W., and Sun X. Antisense hypoxia-inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci. 99 (2008) 2055-2061
43. Bocci G., Nicolaou K.C., and Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62 (2002) 6938-6943
44. Kuhnel F., Zender L., Paul Y., Tietze M.K., Trautwein C., Manns M., and Kubicka S. NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275 (2000) 6421-6427
45. Reuther-Madrid J.Y., Kashatus D., Chen S., Li X., Westwick J., Davis R.J., Earp H.S., Wang C.Y., and Baldwin Jr. A.S. The p65/RelA subunit of NF-kappaB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol. Cell. Biol. 22 (2002) 8175-8183
46. Ortis F., Cardozo A.K., Crispim D., Störling J., Mandrup-Poulsen T., and Eizirik D.L. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappa B activation. Mol. Endocrinol. 20 (2006) 1867-1879
47. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., and Opipari Jr A.W. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276 (2001) 48921-48929
48. Dong Q.G., Sclabas G.M., Fujioka S., Schmidt C., Peng B., Wu T., Tsao M.S., Evans D.B., Abbruzzese J.L., McDonnell T.J., and Chiao P.J. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21 (2002) 6510-6519